Locations:
Search
Research underscores the importance of access to timely diagnosis and treatment in this patient population.
A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.
The shifting role of cell therapy and steroids in the relapsed/refractory setting
Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Addressing rare disease and challenging treatment course in an active young patient
Study shows high rate of hematologic responses, low rate of disease progression
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
Advertisement
Advertisement